2024-518312-40-00招募中1 期
KF2022#1 trial: The effect of fecal microbiota transplantation on CYP enzyme activities
HUS-Yhtymae1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2024年10月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
HUS Diagnostic Center, Clinical Pharmacology unit, Biomedicum
Scientific
HUS-Yhtymae
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Fecal microbiota transplantation for immune checkpoint inhibitors(FMT for ICI)Malignant tumors for which immune check point inhibitors are indicationsJPRN-jRCTs041200003Ohmiya Naoki50
已完成
不适用
A study of usefulness of fecal microbiota transplantation for refractory Clostridium difficile infectioReccurent Clostridium difficile infectionJPRN-UMIN000018731agoya University Graduate School of Medicine, Department of Gastroentrology and hepatology10
已完成
不适用
The effect of consecutive fecal microbiota transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a randomized-controlled trialhepatic fat accumulationNon-Alcoholic Fatty Liver Disease (NAFLD)1001965410013317NL-OMON48776eids Universitair Medisch Centrum20
招募中
不适用
Examination of the utility of the fecal microbiota transplantation for Crohn's diseaseCrohn's diseaseJPRN-UMIN000024633Shiga University of Medical Science40
招募中
不适用
Effects of drug (Tenofovir, FMT, Plasma Exchange therapy) in Liver Disease (ACLF-HBV).CTRI/2020/06/026062Institute of Liver and Biliary Sciences